Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatinin-eligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H. Flaig, T. W., Rosenberg, J. E., Hoimes, C. J., O'Donnell, P. H., Mar, N., Gourdin, T., Henry, S., Bilen, M., George, S., Barata, P. C., Srinivas, S., Rao, S., Assikis, V. J., Burgess, E. F., Ramamurthy, C., Haas, G. P., Lukas, J., Mildiner-Earley, S., Yu, Y., Petrylak, D. P. LIPPINCOTT WILLIAMS & WILKINS. 2023

View details for Web of Science ID 001053772001082